Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced its financial results for the third quarter ended September 30, 2026, and provided an update on its clinical development pipeline. The company is preparing to initiate a pivotal Phase 3 superiority study for its intravenously administered multi-phage product candidate, AP-SA02, which is intended for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive or methicillin-resistant S. aureus.

On the regulatory front, Armata reported that it has submitted protocol revisions in response to feedback from the U.S. Food and Drug Administration (FDA). The company also completed four engineering runs of AP-SA02 at its in-house cGMP manufacturing facility in Los Angeles, California. Clinical trial material production is underway, with one cGMP production run and vialing of the drug product completed during the third quarter. Additionally, the company executed contracts with clinical research organizations to support study management and continued negotiating clinical trial agreements with U.S. sites.

AP-SA02 has received several regulatory designations from the FDA, including Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product status. The company also obtained FDA agreement on an Initial Pediatric Study Plan, which defers pediatric studies pending safety and efficacy data from the planned adult Phase 3 program.

Armata reported that it received $3.7 million in additional non-dilutive funding from the U.S. Department of War, bringing cumulative funding under the award to approximately $32.4 million. The company also announced the issuance of two U.S. patents, including Patent No. 12,751,983, issued October 6, 2026, which protects methods of treating S. aureus infections with AP-SA02.

Financially, for the three months ended September 30, 2026, Armata recognized grant and award revenue of $3.2 million. Research and development expenses were approximately $6.8 million, while general and administrative expenses were approximately $3.7 million. The company reported a net income of $54.9 million, or $1.15 per share on a basic basis, driven by a gain of $69.6 million from changes in the fair value of a convertible loan. As of September 30, 2026, Armata held approximately $18.3 million of unrestricted cash and cash equivalents, compared to $8.7 million as of December 31, 2025.